Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Directors Deals Ltd.
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Jazz Pharmaceuticals PLC Raises FY 2013 Guidance

Tuesday, 7 May 2013 04:05pm EDT 

Jazz Pharmaceuticals PLC updated its fiscal 2013 and expects revenues to be between $830-$860 million, GAAP net income per diluted share to be between $3.32-$3.69 and adjusted net income per diluted share to be between $6.10-$6.30. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $826 and EPS of $5.87 for fiscal 2013 

Company Quote

6.22 +3.65%
26 Nov 2014